Enzymatica AB (publ)
STO:ENZY
Enzymatica AB (publ)
Revenue
Enzymatica AB (publ)
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Enzymatica AB (publ)
STO:ENZY
|
Revenue
kr45.6m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
9%
|
|
|
Calliditas Therapeutics AB
STO:CALTX
|
Revenue
kr1.6B
|
CAGR 3-Years
1 488%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
|
Orexo AB
STO:ORX
|
Revenue
kr590m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
0%
|
|
|
Camurus AB
STO:CAMX
|
Revenue
kr1.9B
|
CAGR 3-Years
46%
|
CAGR 5-Years
78%
|
CAGR 10-Years
N/A
|
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Revenue
kr2.5B
|
CAGR 3-Years
49%
|
CAGR 5-Years
82%
|
CAGR 10-Years
N/A
|
|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Revenue
kr100k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
Enzymatica AB (publ)
Glance View
Enzymatica AB engages in the research, development, and sale of medical technology products. The company is headquartered in Lund, Skane and currently employs 26 full-time employees. The company went IPO on 2011-06-14. The company researches, develops and registers enzyme-based health and wellbeing products. The firm uses a patented enzyme, Penzyme, a cold-adapted trypsin from deep sea cod. The enzyme is active at about 37 Celsius degree and decomposes disease-related proteins, counteracting viral and bacterial infections and supporting healing processes. The firm conducts clinical studies of ColdZyme Munspray, a cold medicine. The company operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others. Main shareholders of Enzymatica AB are Humea AB, Medi AB, and Nordic Consulting Group AB, among others. In November 2013, the Company established another subsidiary in the United States, Enzymatica North America Inc., responsible for future production and sale of veterinary products in the United States and Canada.
See Also
What is Enzymatica AB (publ)'s Revenue?
Revenue
45.6m
SEK
Based on the financial report for Dec 31, 2024, Enzymatica AB (publ)'s Revenue amounts to 45.6m SEK.
What is Enzymatica AB (publ)'s Revenue growth rate?
Revenue CAGR 10Y
9%
Over the last year, the Revenue growth was -10%. The average annual Revenue growth rates for Enzymatica AB (publ) have been -7% over the past three years , -6% over the past five years , and 9% over the past ten years .
You don't have any saved screeners yet